On November 6, Medline Inc. fell 3.09% in Regular Trading, trading at $39.15 per share, with turnover of $23.2741 million.

The clearest catalyst in publicly available coverage is a post-earnings pullback even after UBS raised its target price to $49 from $43 and maintained a Buy rating.

Recent background remains supportive: Medline Inc. previously reported fiscal third-quarter adjusted EPS of $0.44, above the $0.35 consensus, while revenue reached $7.856 billion, topping the expected $7.723 billion and rising from $7.12 billion a year earlier. After the earnings-driven rally, the latest session's weakness appears tied to profit-taking despite the positive analyst target revision.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)